financetom
PAVS
financetom
/
Consumer Staples
/
PAVS
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Paranovus Entertainment Technology Ltd.PAVS
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Paranovus Entertainment Technology Ltd. engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People's Republic of China and internationally.

The company's product category includes lucidum spore powders, cordyceps mycelia, Ejiao products, American ginseng products, other traditional Chinese herbal and animal extracts, vitamins, minerals, and amino acids.

It also offers product marketing and e-commerce agency operation services under the Happy Buy platform to small and middle size businesses; and e-commerce solutions, internet information, and advertising services to the online stores or manufactures.

In addition, the company provides secure transaction environment, automobile procurement, and financial services for automobile manufacturers under the Taochejun automobile sales platform.

It sells its products through distributors, large-scale chain drugstores, malls, and supermarkets under the Happiness brand.

The company was formerly known as Happiness Development Group Limited and changed its name to Paranovus Entertainment Technology Ltd. in March 2023.

The company was founded in 2004 and is headquartered in Nanping, the People's Republic of China.

Latest News >
China leading generative AI patents race, UN report says
China leading generative AI patents race, UN report says
Jul 3, 2024
GENEVA, July 3 (Reuters) - China is far ahead of other countries in generative AI inventions like chatbots, filing six times more patents than its closest rival the United States, U.N. data showed on Wednesday. Generative AI, which produces text, images, computer code and even music from existing information, is exploding with more than 50,000 patent applications filed in the...
Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval
Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval
Jul 3, 2024
04:15 AM EDT, 07/03/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Wednesday the European Commission has approved Dupixent as an additional maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease, or COPD, a respiratory disease that damages the lungs. The decision marks the first Dupixent approval worldwide for COPD patients, the companies...
Eli Lilly Shares Gain After Drug-Maker Gets FDA's Nod For Early Alzheimer's Treatment
Eli Lilly Shares Gain After Drug-Maker Gets FDA's Nod For Early Alzheimer's Treatment
Jul 3, 2024
In a significant development in the battle against Alzheimer’s disease, the U.S. Food and Drug Administration (FDA) has approved Eli Lilly ( LLY ) and Company’s Alzheimer’s treatment, “Kisunla.” What Happened: As per the official press release on Tuesday, Kisunla (donanemab-azbt), a once-monthly IV infusion injection, is intended for adults in the early symptomatic stages of Alzheimer’s disease, including those...
Futu's Wealth Business Surpasses $10 Billion in Assets Under Management
Futu's Wealth Business Surpasses $10 Billion in Assets Under Management
Jul 3, 2024
04:16 AM EDT, 07/03/2024 (MT Newswires) -- Futu Holdings ( FUTU ) said early Wednesday its wealth management business surpassed $10 billion in assets under management. The company also said its fully-owned subsidiary, Moomoo Securities Malaysia, recently received approval from the Federation of Investment Managers Malaysia to distribute wealth management products in the country. Price: 65.89, Change: -0.13, Percent Change:...
Copyright 2023-2025 - www.financetom.com All Rights Reserved